PE20040636A1 - Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina - Google Patents

Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina

Info

Publication number
PE20040636A1
PE20040636A1 PE2003000661A PE2003000661A PE20040636A1 PE 20040636 A1 PE20040636 A1 PE 20040636A1 PE 2003000661 A PE2003000661 A PE 2003000661A PE 2003000661 A PE2003000661 A PE 2003000661A PE 20040636 A1 PE20040636 A1 PE 20040636A1
Authority
PE
Peru
Prior art keywords
ester
valine
methyl
ribofuranosylcitidine
ribofuranosilcitidine
Prior art date
Application number
PE2003000661A
Other languages
English (en)
Inventor
Jean Pierre Sommadossi
Colla Paolo La
Original Assignee
Idenix Cayman Ltd
Univ Cagliari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30003988&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idenix Cayman Ltd, Univ Cagliari filed Critical Idenix Cayman Ltd
Publication of PE20040636A1 publication Critical patent/PE20040636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL ESTER DE 2'-C-METIL-3'-O-L-VALINA DE RIBOFURANOSILCITIDINA, SUS SALES, COMO EL CLORHIDRATO, DERIVADOS, PRODROGAS Y A UN PROCESO DE SINTESIS DE DICHO ESTER. LOS COMPUESTOS RESULTANTES SON AGENTES ANTI-FLAVIVIRIDAE UTILES EN EL TRATAMIENTO DE HEPATITIS C
PE2003000661A 2002-06-28 2003-06-30 Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina PE20040636A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39235002P 2002-06-28 2002-06-28
US39235102P 2002-06-28 2002-06-28
US46619403P 2003-04-28 2003-04-28
US47094903P 2003-05-14 2003-05-14

Publications (1)

Publication Number Publication Date
PE20040636A1 true PE20040636A1 (es) 2004-12-03

Family

ID=30003988

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2003000661A PE20040636A1 (es) 2002-06-28 2003-06-30 Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
PE2003000659A PE20040634A1 (es) 2002-06-28 2003-06-30 Prodrogas 2' y 3' de nucleosidos modificados
PE2003000660A PE20040635A1 (es) 2002-06-28 2003-06-30 Prodrogas 2' y 3' de nucleosidos ramificados

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2003000659A PE20040634A1 (es) 2002-06-28 2003-06-30 Prodrogas 2' y 3' de nucleosidos modificados
PE2003000660A PE20040635A1 (es) 2002-06-28 2003-06-30 Prodrogas 2' y 3' de nucleosidos ramificados

Country Status (27)

Country Link
EP (3) EP2332952B1 (es)
JP (7) JP2005533817A (es)
KR (1) KR20050048544A (es)
CN (6) CN104193791A (es)
AP (1) AP2005003212A0 (es)
AR (2) AR043101A1 (es)
AU (1) AU2003247084B9 (es)
BR (2) BR0312271A (es)
CA (1) CA2490191C (es)
CY (2) CY1115417T1 (es)
DE (1) DE14169110T1 (es)
DK (1) DK1523489T3 (es)
ES (1) ES2469569T3 (es)
HK (3) HK1204624A1 (es)
IL (1) IL165893A0 (es)
MA (1) MA27375A1 (es)
MX (1) MXPA04012709A (es)
MY (1) MY140819A (es)
NO (3) NO330755B1 (es)
PE (3) PE20040636A1 (es)
PL (1) PL374831A1 (es)
PT (1) PT1523489E (es)
RS (1) RS114004A (es)
RU (1) RU2483075C2 (es)
TW (3) TW200500375A (es)
UY (3) UY27874A1 (es)
WO (1) WO2004002999A2 (es)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
CN104193791A (zh) 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
KR101115210B1 (ko) 2002-10-31 2012-04-12 메타베이시스 테라퓨틱스, 인크. 신규 시타라빈 모노포스페이트 전구약물
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
EP3521297B1 (en) 2003-05-30 2021-12-22 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
UA86962C2 (en) 2004-02-20 2009-06-10 Бёрингер Ингельхайм Интернациональ Гмбх Viral polymerase inhibitors
AU2005254057B2 (en) 2004-06-15 2011-02-17 Isis Pharmaceuticals, Inc. C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase
ES2769377T3 (es) 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
EP1804811A4 (en) * 2004-09-24 2011-04-27 Idenix Cayman Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF FLAVIVERS, PESTIVERS AND HEPACIVIRES
WO2006119061A2 (en) 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
CA2615896C (en) 2005-08-01 2012-11-13 Merck & Co., Inc. Macrocyclic peptides as hcv ns3 protease inhibitors
EP1957510A1 (en) 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
WO2007113159A1 (en) 2006-04-04 2007-10-11 F. Hoffmann-La Roche Ag 3',5'-di-o-acylated nucleosides for hcv treatment
GB0609178D0 (en) 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
GB0609492D0 (en) 2006-05-15 2006-06-21 Angeletti P Ist Richerche Bio Therapeutic agents
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
GB0612423D0 (en) 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
WO2008045419A1 (en) 2006-10-10 2008-04-17 Pharmasset, Inc. Preparation of nucleosides ribofuranosyl pyrimidines
RS51643B (en) 2006-10-10 2011-10-31 Medivir Ab. INHIBITOR HCV NUKLEOZIDA
JP2010507656A (ja) 2006-10-24 2010-03-11 メルク エンド カムパニー インコーポレーテッド Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
CA2667266C (en) 2006-10-24 2015-11-24 Merck & Co., Inc. Hcv ns3 protease inhibitors
JP5268927B2 (ja) 2006-10-27 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖｎｓ３プロテアーゼ阻害剤
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
BRPI0718714B8 (pt) 2006-11-09 2021-05-25 Hoffmann La Roche arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
AU2007335962B2 (en) 2006-12-20 2012-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CA2673649A1 (en) 2007-01-05 2008-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2178885A1 (en) 2007-07-17 2010-04-28 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic indole derivatives for the treatment of hepatitis c infections
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
US8648085B2 (en) 2007-11-30 2014-02-11 Boehringer Ingelheim International Gmbh 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
ES2570628T3 (es) 2007-12-17 2016-05-19 Hoffmann La Roche Nuevas arilamidas con sustitución imidazol
CN101903362B (zh) 2007-12-17 2013-07-17 霍夫曼-拉罗奇有限公司 四唑取代的芳基酰胺衍生物和它们作为p2x3和/或p2x2/3嘌呤能受体拮抗物的用途
EP2234976B1 (en) 2007-12-17 2013-04-10 F. Hoffmann-La Roche AG Novel pyrazole-substituted arylamides
BR122018070508B8 (pt) 2007-12-17 2021-07-27 Hoffmann La Roche derivados de arilamida triazol-substituída e seu uso
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CA2722308C (en) 2008-04-15 2024-02-27 Rfs Pharma, Llc. Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections
AU2009241445A1 (en) 2008-04-28 2009-11-05 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
TW201012814A (en) * 2008-07-01 2010-04-01 Centocor Ortho Biotech Products L P Cyclopropyl polymerase inhibitors
ES2458358T3 (es) 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
DK2310095T3 (da) 2008-07-22 2012-12-10 Merck Sharp & Dohme Makrocykliske quinoxalinforbindelser som hcv-ns3-protease-inhibitorer
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经***疾病中的用途
EP2334179A4 (en) 2008-09-08 2012-09-26 Merck Sharp & Dohme AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPERHOMOCYSTEINEEMIA
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
WO2010075517A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside analogs
PA8855801A1 (es) 2008-12-23 2010-07-27 Sintesis de nucleosidos de purina
NZ593648A (en) 2008-12-23 2013-09-27 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
MA33152B1 (fr) 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
ES2450891T3 (es) 2009-06-22 2014-03-25 F. Hoffmann-La Roche Ag Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3
SG176640A1 (en) 2009-06-22 2012-01-30 Hoffmann La Roche Novel oxazolone and pyrrolidinone-substituted arylamides
EP2445897B1 (en) 2009-06-22 2014-03-19 F.Hoffmann-La Roche Ag Novel indazole arylamides as p2x3 and/or p2x2/3 antagonists
WO2011014487A1 (en) 2009-07-30 2011-02-03 Merck Sharp & Dohme Corp. Hepatitis c virus ns3 protease inhibitors
AR077712A1 (es) 2009-08-05 2011-09-14 Idenix Pharmaceuticals Inc Inhibidores de serina proteasa macrociclica
KR20120104239A (ko) 2009-11-14 2012-09-20 에프. 호프만-라 로슈 아게 Ｈｃｖ 치료에 대한 신속한 반응을 예측하기 위한 바이오마커
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
WO2011067195A1 (en) 2009-12-02 2011-06-09 F. Hoffmann-La Roche Ag Biomarkers for predicting sustained response to hcv treatment
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
ES2551944T3 (es) 2010-03-31 2015-11-24 Gilead Pharmasset Llc (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato de isopropilo cristalino
WO2011123586A1 (en) 2010-04-01 2011-10-06 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
NZ603725A (en) 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
JP6069215B2 (ja) 2010-11-30 2017-02-01 ギリアド ファーマセット エルエルシー 化合物
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
BR112013026219A2 (pt) 2011-04-13 2016-07-26 Gilead Sciences Inc análogos de n-nucleosídeo 1'-substituída pirimidina para tratamento antiviral
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
EP2780026B1 (en) 2011-11-15 2019-10-23 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
WO2013133927A1 (en) 2012-02-13 2013-09-12 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
WO2013174962A1 (en) 2012-05-25 2013-11-28 Janssen R&D Ireland Uracyl spirooxetane nucleosides
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
CA2891125A1 (en) * 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
LT2935303T (lt) 2012-12-21 2021-03-25 Janssen Biopharma, Inc. 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
WO2014121417A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2014121418A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
RU2534613C2 (ru) 2013-03-22 2014-11-27 Александр Васильевич Иващенко Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
CN105705511A (zh) 2013-04-12 2016-06-22 艾其林医药公司 用于治疗hcv的氘化核苷前药
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
JP6762873B2 (ja) 2013-09-11 2020-09-30 エモリー・ユニバーシテイ ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
KR102314960B1 (ko) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170066795A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN103992360A (zh) * 2014-04-21 2014-08-20 中美华世通生物医药科技（武汉）有限公司 一种适于工业化生产的还原方法
JP6728075B2 (ja) * 2014-06-24 2020-07-22 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
US11452714B2 (en) 2017-05-23 2022-09-27 Regents Of The University Of Minnesota Antibacterial agents including histidine kinase inhibitors
CN109748943A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 2’-c-甲基取代核苷类化合物及其制备与用途
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111995649A (zh) * 2020-04-09 2020-11-27 瀚海新拓(杭州)生物医药有限公司 一种蝶啶酮核苷酸类似物及其药物组合物、制备方法和医药用途
CN115955978A (zh) * 2020-04-28 2023-04-11 南湖制药公司 干扰素tau作为抗病毒疗法
WO2022008025A1 (en) * 2020-07-05 2022-01-13 Since & Technology Development Fund Authority 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto
WO2022221514A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN112979733B (zh) * 2021-04-25 2021-09-10 南京颐媛生物医学研究院有限公司 抗乙肝病毒的化合物及其制备方法和应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1695411A1 (de) * 1966-05-02 1971-04-15 Merck & Co Inc Substituierte Purin-Nucleoside und Verfahren zu deren Herstellung
FR1521076A (fr) * 1966-05-02 1968-04-12 Merck & Co Inc Nucléosides de purines substituées
US3480613A (en) * 1967-07-03 1969-11-25 Merck & Co Inc 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
US3798209A (en) 1971-06-01 1974-03-19 Icn Pharmaceuticals 1,2,4-triazole nucleosides
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
FR2562543B1 (fr) 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
JP2706666B2 (ja) * 1987-07-31 1998-01-28 大鵬薬品工業株式会社 ２’−デオキシ−５−フルオロウリジン誘導体及びその塩
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
JPH03501253A (ja) 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
EP0346108A3 (en) * 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
JPH0368564A (ja) 1989-04-27 1991-03-25 Tsumura & Co 核酸誘導体
JPH032193A (ja) * 1989-05-30 1991-01-08 Ube Ind Ltd ５―フルオロウリジン及び２′―デオキシー５―フルオロウリジン誘導体
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
JPH0383994A (ja) * 1989-08-28 1991-04-09 Kuraray Co Ltd ２’―デオキシ―５―フルオロウリジン誘導体及びその塩、その製造方法並びにそれを有効成分として含有する抗腫瘍剤
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5026687A (en) 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DE69132332T2 (de) 1990-04-06 2000-11-30 Genelabs Tech Inc Hepatitis c-virus-epitope
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
EP0531452A4 (en) 1990-05-29 1993-06-09 Vical, Inc. Synthesis of glycerol di- and triphosphate derivatives
WO1991019721A1 (en) 1990-06-13 1991-12-26 Arnold Glazier Phosphorous produgs
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5256641A (en) 1990-11-01 1993-10-26 State Of Oregon Covalent polar lipid-peptide conjugates for immunological targeting
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5157027A (en) 1991-05-13 1992-10-20 E. R. Squibb & Sons, Inc. Bisphosphonate squalene synthetase inhibitors and method
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en) 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
TW224053B (es) 1991-09-13 1994-05-21 Paul B Chretien
JPH0597887A (ja) * 1991-10-02 1993-04-20 Tanabe Seiyaku Co Ltd 新規２’−デオキシ−５−フルオロウリジン誘導体
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
GB9226729D0 (en) 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
JPH06211890A (ja) * 1993-01-12 1994-08-02 Yamasa Shoyu Co Ltd ２’−デオキシ−２’（ｓ）−置換アルキルシチジン誘導体
JPH06228186A (ja) * 1993-01-29 1994-08-16 Yamasa Shoyu Co Ltd ２’−デオキシ−（２’ｓ）−アルキルピリミジンヌクレオシド誘導体
US5496546A (en) 1993-02-24 1996-03-05 Jui H. Wang Compositions and methods of application of reactive antiviral polyadenylic acid derivatives
CA2162574A1 (en) 1993-05-12 1994-11-24 Karl Y. Hostetler Acyclovir derivatives for topical use
EP0773029A4 (en) 1993-07-19 1997-09-03 Tokyo Tanabe Co HEPATITIS C VIRUS PROLIFERATION INHIBITOR
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
DE4447588C2 (de) 1994-05-03 1997-11-20 Omer Osama Dr Dr Med Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden
DE4432623A1 (de) 1994-09-14 1996-03-21 Huels Chemische Werke Ag Verfahren zur Bleichung von wäßrigen Tensidlösungen
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5696277A (en) 1994-11-15 1997-12-09 Karl Y. Hostetler Antiviral prodrugs
JP3786447B2 (ja) 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
GB9606264D0 (en) * 1995-07-13 1996-05-29 Hoffmann La Roche Pyrimidine nucleoside derivatives
DE69635864T2 (de) 1995-09-27 2006-10-26 Emory University Rekombinante rna-replikase von hepatitis-c-virus
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5980884A (en) 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
JP2000506010A (ja) 1996-02-29 2000-05-23 イミューソル インコーポレイテッド Ｃ型肝炎ウイルスリボザイム
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5830905A (en) 1996-03-29 1998-11-03 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
GB9609932D0 (en) 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
US5891874A (en) 1996-06-05 1999-04-06 Eli Lilly And Company Anti-viral compound
US5837257A (en) 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JP3927630B2 (ja) 1996-09-27 2007-06-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウイルス感染症の予防・治療剤
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CA2266889A1 (en) * 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
AU735438B2 (en) * 1996-11-12 2001-07-05 Medivir Ab Nucleosides
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
IL119833A (en) 1996-12-15 2001-01-11 Lavie David Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
EP1009732B1 (en) 1997-06-30 2003-05-21 MERZ + CO. GmbH & Co. 1-amino-alkylcyclohexane nmda receptor antagonists
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
DE69810822T2 (de) 1997-09-21 2003-11-20 Schering Corp Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infection
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
EP2390257A1 (en) 1998-02-25 2011-11-30 Emory University 2'-fluoronucleosides
AU767599B2 (en) 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
GB9806815D0 (en) 1998-03-30 1998-05-27 Hoffmann La Roche Amino acid derivatives
ES2172288T3 (es) 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
SI1087778T1 (sl) 1998-06-08 2006-02-28 Hoffmann La Roche Uporaba peg-ifn-alfa in ribavirina za zdravljenje kronicnega hepatitisa c
DK1431304T3 (en) 1998-08-10 2015-03-02 Novartis Ag Beta - L-2'-deoxynucleosides for the treatment of hepatitis B
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
FR2784892B1 (fr) 1998-10-23 2001-04-06 Smith & Nephew Kinetec Sa Attelle de mobilisation passive repliable pour membre inferieur
CA2354536A1 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
NZ513728A (en) 1999-03-05 2001-09-28 Metabasis Therapeutics Inc Novel phosphorus-containing prodrugs
JP4979866B2 (ja) 1999-09-08 2012-07-18 リガンド・ファーマシューティカルズ・インコーポレイテッド 肝臓に特異的なドラッグデリバリーのためのプロドラッグ
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US6965033B2 (en) 1999-12-22 2005-11-15 Metabasis Therapeutics, Inc. Bisamidate phosphonate prodrugs
WO2001060315A2 (en) * 2000-02-18 2001-08-23 Shire Biochem Inc. Method for the treatment or prevention of flavivirus infections using nucleoside analogues
KR20100003313A (ko) 2000-04-13 2010-01-07 파마셋 인코포레이티드 간염 바이러스 감염 치료를 위한 3'- 또는 2'-하이드록시메틸 치환된 뉴클레오시드 유도체
WO2001081359A1 (en) 2000-04-20 2001-11-01 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) * 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
ES2227203T3 (es) * 2000-05-26 2005-04-01 Idenix (Cayman) Limited Metodos para tratar la infeccion por el virus de la hepatitis delta con beta-1-2'-desoxinucleosidos.
MY141594A (en) 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
HUP0303358A3 (en) 2000-07-21 2005-10-28 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2002213343A1 (en) 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
KR101005299B1 (ko) 2000-10-18 2011-01-04 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
EP1343807B1 (en) 2000-12-12 2009-04-29 Schering Corporation Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
AU2002230764A1 (en) 2000-12-13 2002-06-24 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
EP1366055A2 (en) 2000-12-15 2003-12-03 Pharmasset Limited Antiviral agents for treatment of flaviviridae infections
CZ20032005A3 (en) 2001-01-22 2004-04-14 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003024461A1 (en) 2001-09-20 2003-03-27 Schering Corporation Hcv combination therapy
WO2003068244A1 (en) * 2002-02-13 2003-08-21 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
CN1653077A (zh) * 2002-05-06 2005-08-10 健亚生物科技公司 治疗c型肝炎病毒感染的核苷衍生物
AU2003251524A1 (en) * 2002-06-17 2003-12-31 Isis Pharmaceuticals, Inc. Carbocyclic nucleoside analogs as RNA-antivirals
WO2004003000A2 (en) * 2002-06-28 2004-01-08 Idenix (Cayman) Limited 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections
CN104193791A (zh) * 2002-06-28 2014-12-10 埃迪尼克斯医药公司 用于治疗黄病毒感染的修饰的2’和3’-核苷前药
EP3521297B1 (en) 2003-05-30 2021-12-22 Gilead Pharmasset LLC Modified fluorinated nucleoside analogues

Also Published As

Publication number Publication date
CN103319554A (zh) 2013-09-25
UY27875A1 (es) 2003-12-31
EP2332952B1 (en) 2015-04-29
WO2004002999A8 (en) 2005-02-17
PL374831A1 (en) 2005-10-31
JP2010280660A (ja) 2010-12-16
IL165893A0 (en) 2006-01-15
CY2014031I1 (el) 2016-06-22
DK1523489T3 (da) 2014-06-16
NO330755B1 (no) 2011-07-04
HK1204625A1 (en) 2015-11-27
AU2003247084B2 (en) 2010-02-11
BR0312286A (pt) 2007-06-19
AU2003247084B9 (en) 2018-07-26
CY2014031I2 (el) 2016-06-22
WO2004002999A3 (en) 2004-08-12
CN102424698A (zh) 2012-04-25
NO2014019I1 (no) 2014-07-30
AR043101A1 (es) 2005-07-20
UY27874A1 (es) 2003-12-31
TW200500373A (en) 2005-01-01
JP2015205885A (ja) 2015-11-19
PE20040634A1 (es) 2004-12-03
ES2469569T3 (es) 2014-06-18
TW200500375A (en) 2005-01-01
EP2799442A1 (en) 2014-11-05
JP2018076342A (ja) 2018-05-17
EP2332952A1 (en) 2011-06-15
KR20050048544A (ko) 2005-05-24
UY27876A1 (es) 2003-12-31
CA2490191A1 (en) 2004-01-08
PE20040635A1 (es) 2004-12-03
JP6069410B2 (ja) 2017-02-01
RS114004A (en) 2007-02-05
RU2011133741A (ru) 2013-02-20
CN100348607C (zh) 2007-11-14
HK1204624A1 (en) 2015-11-27
CA2490191C (en) 2010-08-03
JP2011251983A (ja) 2011-12-15
CN104193791A (zh) 2014-12-10
JP6069169B2 (ja) 2017-02-01
JP2017061480A (ja) 2017-03-30
AR043298A1 (es) 2005-07-27
AU2003247084B8 (en) 2010-03-11
JP2005533817A (ja) 2005-11-10
NO20050465L (no) 2005-01-27
PT1523489E (pt) 2014-06-24
DE14169110T1 (de) 2022-05-12
JP2014058537A (ja) 2014-04-03
EP1523489A2 (en) 2005-04-20
AP2005003212A0 (en) 2005-03-31
MXPA04012709A (es) 2005-09-30
BR0312271A (pt) 2007-11-06
JP6309590B2 (ja) 2018-04-11
WO2004002999A2 (en) 2004-01-08
EP1523489B1 (en) 2014-03-12
MY140819A (en) 2010-01-29
CN104163841B (zh) 2016-08-24
NO20110343A1 (no) 2011-03-04
MA27375A1 (fr) 2005-06-01
CN1678621A (zh) 2005-10-05
CN103275159A (zh) 2013-09-04
TW200500374A (en) 2005-01-01
AU2003247084A1 (en) 2004-01-19
RU2483075C2 (ru) 2013-05-27
HK1206361A1 (en) 2016-01-08
CN104163841A (zh) 2014-11-26
CY1115417T1 (el) 2016-06-22
JP5463332B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
PE20040636A1 (es) Ester de 2'-c-metil-3'-o-l-valina de ribofuranosilcitidina
UY27918A1 (es) Derivados de benzodioxol
UY26721A1 (es) Nuevos derivados de la fenilglicina
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
PA8592001A1 (es) Activadores de glocoquinasa heteroaromaticos de seis miembros 5-sustituidos
ECSP088184A (es) Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades óseas
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
ECSP055945A (es) Compuestos de pirazolotriazina y usos de los mismos
UY27774A1 (es) Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP045497A (es) "difenilazetidinonas sustituidas con grupos acidos, metodo para su producción, medicamentos que comprenden dichos compuestos y su uso"
GT200300284A (es) Derivados de 3h-quinazolin-4-ona
PA8581201A1 (es) Nuevos derivados de tiazol
GT200100145A (es) Derivados de pirrolidina.
PA8581701A1 (es) Derivados de indolilo
UY27930A1 (es) Derivados de tiazol
ATE475663T1 (de) Lamellarinanaloga mit antitumorwirkung
UY26846A1 (es) Derivados de la pirrolidina
BR0317719A (pt) Derivados de fosforamida
UY28145A1 (es) Nuevos compuestos farmaceuticos
PA8558901A1 (es) Nuevos compuestos hexaciclicos
ES2169909T3 (es) 5-hidroximetil-2-aminotetralinas como agentes cardiovasculares.
CY1106385T1 (el) Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου
AR030818A1 (es) Feniluracilos substituidos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed